These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 8188128)

  • 1. [Safety of ACE-inhibitors, how to proceed in limited renal function. Proceedings from a workshop. Munich, 22 September 1993].
    Fortschr Med Suppl; 1994; 163():1-11. PubMed ID: 8188128
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin converting enzyme inhibitors, calcium channel blockers, and their combination in the treatment of glomerular disease.
    Ritz E; Orth SR; Strzelczyk P
    J Hypertens Suppl; 1997 Mar; 15(2):S21-6. PubMed ID: 9218194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomics of angiotensin converting enzyme inhibitors in renal disease--pathophysiological considerations.
    Rudnicki M; Mayer G
    Pharmacogenomics; 2003 Mar; 4(2):153-62. PubMed ID: 12605549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Losartan as an alternative to ACE inhibitors in patients with renal dysfunction.
    Esmail ZN; Loewen PS
    Ann Pharmacother; 1998 Oct; 32(10):1096-8. PubMed ID: 9793603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
    Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D
    Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fosinopril in the treatment of cardiorenal syndrome in chronic cardiac failure].
    Tereshchenko SN; Zhirov IV
    Ter Arkh; 2009; 81(5):84-8. PubMed ID: 19537594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelial function and the kidney. An emerging target for cardiovascular therapy.
    Rabelink TJ; Koomans HA
    Drugs; 1997; 53 Suppl 1():11-9. PubMed ID: 9034751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.
    Bhatnagar V; O'Connor DT; Schork NJ; Salem RM; Nievergelt CM; Rana BK; Smith DW; Bakris GL; Middleton JP; Norris KC; Wright JT; Cheek D; Hiremath L; Contreras G; Appel LJ; Lipkowitz MS
    J Hypertens; 2007 Oct; 25(10):2082-92. PubMed ID: 17885551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE-inhibitors versus angiotensin receptor blockers for renoprotection: conclusions from the evidence and from the evidence behind the evidence.
    Van Biesen W; Van Vlem B; Schepkens H; Lameire N
    Acta Clin Belg; 2001; 56(5):279-83. PubMed ID: 11770222
    [No Abstract]   [Full Text] [Related]  

  • 10. ACE inhibitors and the kidney. A risk-benefit assessment.
    Navis G; Faber HJ; de Zeeuw D; de Jong PE
    Drug Saf; 1996 Sep; 15(3):200-11. PubMed ID: 8879974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal failure and ACE inhibition: how much is too much?
    Gross ML; Adamczak M; Ritz E
    Z Kardiol; 2005 Feb; 94(2):81-6. PubMed ID: 15674737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is administration of preoperative angiotensin-converting enzyme inhibitors important for renal protection after cardiac surgery?
    Dag O; Kaygin MA; Aydin A; Limandal HK; Arslan Ü; Kiymaz A; Kahraman N; Calik ES; Erkut B
    Ren Fail; 2013; 35(5):754-60. PubMed ID: 23521631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Question: does isosorbide dinitrate/hydralazine therapy benefit systolic heart failure patients with renal insufficiency?
    Pan L; Payne J; Clark M
    J Okla State Med Assoc; 2011 Feb; 104(2):49-50. PubMed ID: 21815321
    [No Abstract]   [Full Text] [Related]  

  • 14. Targeting the renin angiotensin system in dialysis patients.
    Cravedi P; Remuzzi G; Ruggenenti P
    Semin Dial; 2011; 24(3):290-7. PubMed ID: 21682771
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of calcium antagonists and worsening renal function in patients receiving angiotensin-converting-enzyme inhibitors.
    Zuccalà G; Onder G; Pedone C; Cesari M; Marzetti E; Cocchi A; Carbonin P; Bernabei R
    Eur J Clin Pharmacol; 2003 Feb; 58(10):695-9. PubMed ID: 12610747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial.
    Solomon SD; Rice MM; A Jablonski K; Jose P; Domanski M; Sabatine M; Gersh BJ; Rouleau J; Pfeffer MA; Braunwald E;
    Circulation; 2006 Jul; 114(1):26-31. PubMed ID: 16801465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of ACE inhibitors as renoprotective agents in Medicaid patients with diabetes.
    Scarsi KK; Bjornson DC
    Ann Pharmacother; 2000 Sep; 34(9):1002-6. PubMed ID: 10981244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control.
    Pines A; Fisman EZ
    Am J Cardiovasc Drugs; 2003; 3(5):351-60. PubMed ID: 14728069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Nephrology 2007].
    Hugo C
    Dtsch Med Wochenschr; 2007 Jun; 132(25-26):1373-5. PubMed ID: 17570083
    [No Abstract]   [Full Text] [Related]  

  • 20. Add-on angiotensin receptor blocker in patients who have proteinuric chronic kidney diseases and are treated with angiotensin-converting enzyme inhibitors.
    Kanno Y; Takenaka T; Nakamura T; Suzuki H
    Clin J Am Soc Nephrol; 2006 Jul; 1(4):730-7. PubMed ID: 17699280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.